1.84 -0.03 (-1.60%)
After hours: 4:25PM EST
|Bid||1.80 x 19500|
|Ask||1.89 x 100|
|Day's Range||1.81 - 1.90|
|52 Week Range||0.93 - 3.84|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Categories: Yahoo FinanceIsmailia National Food Industries relative valuation is now NEUTRAL. It was previously rated OVERVALUED, and has a fundamental analysis score of 47. Our analysis is based on comparing Ismailia National Food Industries with the following peers – Ismailia Misr Poultry, Atlas for Land Reclamation & Agricultural Processing, Sharkia National Food and Arab Cotton Ginning Co. ... Read more (Read more...)
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 14 cents. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
Infinity Pharmaceuticals Inc. (NASDAQ: INFI ) shares are soaring Thursday after an upgrade by Wells Fargo. The biopharma company's IPI-549 monotherapy data was selected for a "late-breaker" oral ...
Infinity (INFI) expanded its existing clinical collaboration with Bristol-Myers Squibb for evaluating IPI-549 in combination with Opdivo to include patients with triple negative breast cancer.
Infinity Pharmaceuticals, Inc. (INFI) reported a wider-than-expected loss in second-quarter 2017 due to the termination of an agreement with AbbVie.
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 34 cents. In the final minutes of trading on Thursday, the company's shares hit $1.36. A year ago, they were trading ...
Infinity Pharmaceuticals (INFI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Prothena Corporation plc (PRTA) reported a loss of 99 cents per share in the first quarter of 2017, wider than the year-ago loss of 81 cents.
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 21 cents. In the final minutes of trading on Tuesday, the company's shares hit $1.84. A year ago, they were trading ...
Endo International plc's (ENDP) first-quarter 2017 earnings from continuing operations was $1.23 per share which topped the Zacks Consensus Estimate of $1.12. Earnings were also above the year-ago figure of $1.08.
Horizon Pharma plc (HZNP) reported first-quarter 2017 earnings of 21 cents per share, down from 25 cents in the year-ago quarter. Reported earnings also missed the Zacks Consensus Estimate of 25 cents.
Agenus Inc. (AGEN) reported first-quarter 2017 loss of 18 cents per share (including non-cash expenses), narrower than the Zacks Consensus Estimate of a loss of 32 cents and the year-ago loss of 37 cents.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Infinity Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to INFI-US. Comparing the performance and risk of Infinity Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Ultragenyx Pharmaceutical Inc. (RARE) and its Japanese partner Kyowa Hakko Kirin Co., Ltd announced positive data from a phase III study evaluating its pipeline candidate burosumab (KRN23) in adults with X-linked hypophosphatemia (XLH).
Infinity (INFI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.